ReviewFrontiers in immunology2021
Mesenchymal Stromal Cells for the Treatment of Graft Versus Host Disease.
Review in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 98 citations in OpenAlex.
- Co-infusion of mesenchymal stromal cells to prevent GVHD after allogeneic hematopoietic cell transplantation from HLA-mismatched unrelated donors after reduced-intensity conditioning: a double-blind randomized study and literature review.Stem cell research & therapy · 2024Trial
- Human placental mesenchymal stromal cell-derived small extracellular vesicles as a treatment for severe COVID-19: A double-blind randomized controlled clinical trial.Journal of extracellular vesicles · 2024Trial
- Repeated Infusions of Bone-Marrow-Derived Mesenchymal Stem Cells over 8 Weeks for Steroid-Refractory Chronic Graft-versus-Host Disease: A Prospective, Phase I/II Clinical Study.International journal of molecular sciences · 2024Trial
- A Review of Modern Therapies and New Innovations in the Treatment of Cutaneous Graft-versus-Host Disease.Dermatology and therapy · 2026Review
- Cell Therapy and Graft Engineering for Chronic Graft-versus-host Disease.Stem cell reviews and reports · 2026Review
- Mesenchymal Stem Cells and Extracellular Vesicles: Bridging the Translational Gap in Regenerative Medicine.International journal of molecular sciences · 2026Article
- The impact of mesenchymal stromal cells on the proliferation and functional maturation of liver organoids.Biology direct · 2026Article
- Targeting Oxidative and Nitrosative Stress: Mechanistic Insights and Therapeutic Strategies for Radiation-Induced Lung Injury.Journal of inflammation research · 2026Review
- Assessment of Vedolizumab and UC-MSC interaction and therapeutic potential in acute graft-versus-host-disease.Frontiers in cell and developmental biology · 2026Article
- Isolation and characterization of CD73+CD39+CD146+ mesenchymal stem cell subset from bone marrow.World journal of stem cells · 2025Article
- The roles and clinical applications of mesenchymal stem cells and their exosomes in hematologic diseases.Stem cell research & therapy · 2025Review
- MSCohi-O lenses attenuate corneal transplant rejection via HLA-G5 driven Treg cell expansion.BMC ophthalmology · 2025Article
- Advances in Innovative Surgical Implant Manufacturing for Hernia Repair and Soft Tissue Reconstruction.Bioengineering (Basel, Switzerland) · 2025Review
- Mesenchymal stem cell-derived microRNAs: Key immunomodulators to prevent ocular tissue degeneration.World journal of stem cells · 2025Review
- Microvesicles secreted by CoClAnnals of hematology · 2025Article
- The Impact of IFN-γ Licensing on Mesenchymal Stromal Cells' Mediated Immunoregulation and HLA Class II Expression: Emerging Evidence from In Vitro Results.International journal of molecular sciences · 2025Article
- Therapeutic Potential of Chimeric Antigen Receptor-Expressing Mesenchymal Stem Cells in the Treatment of Inflammatory and Autoimmune Diseases.International journal of molecular sciences · 2025Review
- Conditioned media of stem cells from human exfoliated deciduous teeth contain factors related to extracellular matrix organization and promotes corneal epithelial wound healing.Regenerative therapy · 2025Article
- Addressing graft-versus-host disease in allogeneic cell-based immunotherapy for cancer.Experimental hematology & oncology · 2025Review
- Immunoregulatory iPSC-derived non-lymphoid progeny in autoimmunity and GVHD alloimmunity.Stem cells (Dayton, Ohio) · 2025Review
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Graft versus host disease (GvHD) is a life-threating complication of allogeneic hematopoietic stem cell transplantation, which is initially treated with high dose corticosteroids. Approximately 50% of acute GvHD cases are resistant to steroid treatment, and two-year mortality rates in those steroid-resistant patients exceed 80%. Chronic GvHD necessitates prolonged corticosteroid use, which is typically associated with limited efficacy and troublesome adverse effects. No agent has yet been established as an optimal second line therapy for either acute or chronic GvHD, but mesenchymal stromal cells (MSCs) have shown substantial promise. MSCs promote an immunosuppressive and immunoregulatory environment
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.